JESSE HERRMAN: Open Payments
NPI 1154198562 · COLUMBUS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,370 in 73 payments from 14 companies in 2025. Trend: 2023 $208 · 2024 $1,418 · 2025 $1,370
Food & beverage: $1,362Education: $8
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 20 | $470 |
| Vanda Pharmaceuticals Inc. | 6 | $173 |
| ABBVIE INC. | 13 | $148 |
| Alkermes, Inc. | 12 | $136 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $76 |
| Teva Pharmaceuticals USA, Inc. | 4 | $72 |
| Neurocrine BioSciences, Inc. | 3 | $63 |
| Janssen Pharmaceuticals, Inc | 2 | $46 |
| Collegium Pharmaceutical, Inc. | 2 | $42 |
| Luye Pharma (USA) Ltd. | 1 | $34 |
Products named: REXULTI, FANAPT, ABILIFY MAINTENA, VRAYLAR, ABILIFY ASIMTUFII, ARISTADA, CAPLYTA, INGREZZA.
Industry payments across IN — which companies pay providers there.
